Education
About Us
Working with TipRanks
Follow Us
Cencora (COR)
NYSE:COR
COR Stock Chart & Stats
$342.96
$2.86(1.22%)
At close: 4:00 PM EST
$342.96
$2.86(1.22%)
Day’s Range― - ―
52-Week Range$223.92 - $377.54
Previous CloseN/A
Volume440.68K
Average Volume (3M)1.63M
Market Cap
$66.29B
Enterprise Value$63.90B
Total Cash (Recent Filing)$4.36B
Total Debt (Recent Filing)$7.66B
Price to Earnings (P/E)42.9
Beta0.05
Next Earnings
Feb 04, 2026EPS Estimate
4.04Next Dividend Ex-DateN/A
Dividend Yield0.66%
Share Statistics
EPS (TTM)3.84
Shares Outstanding193,993,440
10 Day Avg. Volume1,718,975
30 Day Avg. Volume1,630,418
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit5.57
Enterprise Value/Ebitda17.23
Forecast
1Y Price Target
$392.82Price Target Upside14.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)17.65
Revenue Forecast (FY)$341.13B
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of OneOncology is consistent with Cencora’s capital deployment strategy.
Financial GuidanceCencora raised its long-term guidance for adjusted operating income and adjusted EPS to reflect the long-term contributions from OneOncology.
Market PositioningCencora appears well positioned to drive synergies in drug purchasing and other operational areas.
Bears Say
Share RepurchaseCencora is pausing share repurchases in anticipation of the OneOncology acquisition.
Cencora News
COR FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was $223.92 and its highest was $377.54 in the past 12 months.
What is Cencora’s market cap?
Cencora’s market cap is $66.29B.
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Feb 04, 2026 which is in 48 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Nov 05, 2025. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.787 by $0.053.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.66%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is 4.04.
How many shares outstanding does Cencora have?
Cencora has 193,993,440 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $3.84 in its last earnings report, beating expectations of $3.787. Following the earnings report the stock price went up 2.75%.
Which hedge fund is a major shareholder of Cencora?
Currently, no hedge funds are holding shares in COR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$392.82 (14.54% Upside)
$392.82 (14.54% Upside)
Blogger Sentiment
Bullish
COR Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 385.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.82%
12-Months-Change
Fundamentals
Return on Equity
144.31%
Trailing 12-Months
Asset Growth
14.14%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
COR Company Deck
COR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cencora reported strong financial performance for fiscal 2025 with significant growth in operating income and EPS. The company raised its long-term guidance and made substantial investments in infrastructure to support future growth. Challenges were noted in the PharmaLex business, resulting in a significant goodwill impairment. However, the overall sentiment is positive due to the strong performance and strategic positioning in the specialty market.View all COR earnings summariesCOR Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations
COR Stock 12 Month Forecast
Average Price Target
$392.82
▲(14.54% Upside)
Technical Analysis
Ownership Overview
6.82% Insiders
29.05% Mutual Funds
16.28% Other Institutional Investors
21.28% Public Companies and Individual Investors
Options Prices
Currently, No data available
---